


Meeting Date: March 5, 2026
Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order		5:01 PM EST		
A. Minutes from previous meetings		Review of Minutes from December 11, 2025	Minutes reviewed, approved	Yes
B. Hot Topic		Respiratory Syncytial Virus (RSV) Prevention	Non-voting item	
C. Formulary Review - New Drugs		Dawizera	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Inluriyo	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Palsonify	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Forzinity	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Jascayd	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Konzifti	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Rhapsido	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		loratadine chewable tablet	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Preferred across all applicable lines of business		
		montelukast granules	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Preferred, max age of 6 across all applicable lines of business		
		Wayniz	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Leqembi Iqlik	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		galantamine ER	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Preferred across all applicable lines of business		
		memantine HCl	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Lynkuet	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
D. Formulary Review - New Formulations		Confirm Review of New Formulations Grid	Yes/No	Yes
		Recommendation: • Tommy: Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
E. Formulary Review - Audit Grid		Confirm Review of Audit Grid	Yes/No	Yes
		Adakveo	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business		
		Vyepti	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business		
		Sarclisa	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business		
		Trodelvy	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business		
		Darzalex Faspro	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business		
		Jatenzo	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Arazlo	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Licart	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Davyigo	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Koselugo	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Pemazyre	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Qinlock	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Retevmo	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Tabrecta	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Tukysa	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Xcopri	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		
		Zerviate	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business		

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
F. Formulary Review - PDL Modifications		Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • linezolid oral tablet/suspension: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • praziquantel oral tablet: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Nucala subcutaneous injection: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • perphenazine/amitriptyline oral tablet: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • mirtazapine ODT: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • s/Rowasa suspension enema: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Lancets: Move additional NDCs to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • nystatin triamcinolone cream/ointment: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • disopyramide oral capsule: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • butalbital/acetaminophen/caffeine oral capsule: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • clonidine topical patch: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • trimethoprim oral capsule: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Promethgan 50 mg suppository: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Starjamza subcutaneous injection: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
G. Formulary Review - New Drugs- Medical		Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Inleexo		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Papzimeos		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Bienrep		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Hymovis One		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Lymphir		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
H. Formulary Review - Drugs Evaluated Per Grid		Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	10:0
I. Clinical Guidelines		Clinical Guideline Review	Yes/No	Yes
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	10:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	10:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	10:0
J. Quality Monitoring		Confirm Review of Quality Data	Yes/No	Yes
		DUR Review - Lock-in		
		Drug Recalls - 4th Quarter 2025		
		Top 25 Drugs by Spend and Volume - 4th Quarter 2025		
		Top 10 Drugs Requested - Approvals and Denials - 4th Quarter 2025		
		Grievances and Appeals Data - 4th Quarter 2025		
		Inter-Rater Reliability (IRR) - 4th Quarter 2025		
		• Pharmacists		
Adjournment		6:45 PM EST		
Respectfully Submitted to the Committee.				
 M.S.I.A., R.Ph. Chief Pharmacy Officer, UHC C&S				